Navigation Links
Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
Date:2/18/2009

ents. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding the timing of ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, the timing of CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure, our ability to generate efficacy and safety data required for the marketing approval of ATPace, and the effects of the initial doses of ATPace. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
2. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
3. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
4. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
5. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
6. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
7. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
8. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
9. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
10. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
11. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... is one of the top public health concerns in ... 2-19 classified as obese as of 2012. As health ... have taken to Twitter to discuss the problem. , ... assistant professor at the Brown School at Washington University ... #childhoodobesity in tweets to track Twitter conversations about the ...
(Date:7/10/2014)... medical imaging far outweigh the risks when children receive ... Right Radiation Dose. However, overuse and misuse of imaging ... a collaborative effort to ensure a national protocol is ... Journal of Patient Safety , calls for the ... Accreditation Commission, and the Centers for Medicare & Medicaid ...
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
(Date:7/9/2014)... a small increased risk of prostate cancer, and a ... to a new study from Harvard School of Public ... even among men who received regular PSA screening, suggesting ... by diagnostic bias. It is the largest and most ... between vasectomy and prostate cancer. , The study appears ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2
... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, held a Board ... which a new,Board member was appointed to serve ... an Audit Committee and a Compensation Committee were ...
... 23 Laura Kolkman, President,Mosaica Partners, a ... been selected to serve as Chair of ... Healthcare Information,Exchange (HIE) Steering Committee., The ... all HIE,stakeholders including providers, payers, vendors, consultants ...
... new survey of employers by the,non-profit Midwest Business Group ... the Smoke-free Illinois Act*, helps companies and,their employees overcome ... a challenge., MBGH conducted its second annual Smoking ... level of employer involvement in reducing tobacco,use among workers. ...
... up on innuendo and social cues is a central component ... to determine another person,s intentions in a social interaction. New ... mechanisms that are responsible for such social difficulties in autism, ... all of us. , According to the study, which ...
... by Edison Pharma , ... Boston (PRWEB) July 23, ... Guide to MITO Management, a comprehensive online resource designed to assist ... affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management ...
... of free web meeting software has recently added advanced features like shared ... far, these features were only available for a high cost with paid ... Desktop Service, which lets you log into your home or office PC ... ...
Cached Medicine News:Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 3Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers 2Health News:How to Conduct Free Web Meetings and Remote Desktop? 2
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... Jan. 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to ... North America . NuAire will utilize its network of sales ... Canada to offer assistance in application use, product ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Imagine the benefits if there was technology that pinpointed ... individual,s type of cancer. No more guessing. No more ... lifesaving technology is on its way to becoming reality. ... Wilshire Oncology Medical Group are yielding positive results. Wilshire ...
... THOR ), a world leader in device-based mechanical ... announced today that it has given notice of its intention ... due 2034 (CUSIP No. 885175AA7) (the "Notes") on May 17, ... outstanding, which can be converted into 7.2 million shares of ...
Cached Medicine Technology:California Oncology Group Uses New Technology to Choose Best Cancer Treatment 2California Oncology Group Uses New Technology to Choose Best Cancer Treatment 3Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 2Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034 3
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
... in Critical Care & Emergency Medicine. ... cordless, and simple to use device which ... of the pupillary light reflex (PLR). Now ... which are not discernable to the naked ...
... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
... VenaCure Laser Vein Treatment. It is estimated ... worldwide have varicose veins. In the United States, ... of 60 suffer from painful and unsightly venous ... the capabilities of vascular therapy for the treatment ...
Medicine Products: